Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 124 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Esomeprazole Clear all

Conditions: GERD Without Erosive Esophagitis
Interventions: AZD0865; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 77
States / cities: Alabaster, Alabama • Huntsville, Alabama • Tucson, Arizona + 74 more

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), Diclofenac/Misoprostol; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Dyspepsia
Interventions: Esomeprazole Magnesium; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy
Interventions: Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Gastroesophageal Reflux
Interventions: Nexium, Sugar Pill; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: vepdegestrant, esomeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pharmacokinetics
Interventions: esomeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: Up to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 11
States / cities: Little Rock, Arkansas • Hartford, Connecticut • Park Ridge, Illinois + 8 more

Conditions: Esophagitis
Interventions: esomeprazole, fluticasone; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Effect of Food, Pharmacokinetics
Interventions: esomeprazole/ASA Fixed Dose Combination (FDC); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Oveland Park, Kansas

Conditions: Healthy Study Participants
Interventions: UCB0599, Esomeprazole, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), PN 400 (VIMOVO); Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy Participants
Interventions: BBT-877, Midazolam, Itraconazole, Esomeprazole; Drug
Lead sponsor: Bridge Biotherapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Gastroesophageal Reflux Disease
Interventions: IW-3718, Matching Placebo, PPI; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 62
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Rabeprazole sodium, Esomeprazole; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,069 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Moline, Illinois

Conditions: Eosinophilic Esophagitis
Interventions: Swallowed fluticasone, Esomeprazole; Drug
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Osteoarthritis
Interventions: PN 400 (VIMOVO), celebrex, Placebo, Rescue Antacid; Drug
Lead sponsor: POZEN; Industry
Eligibility: 50 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Nausea, Vomiting, Abdominal Pain
Interventions: esomeprazole (PPI); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteers
Interventions: Aspirin, Esomeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Asthma, GERD
Interventions: Esomeprazole, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 27
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 24 more

Conditions: Gastric Ulcer
Interventions: PN400 (VIMOVO), Naproxen; Drug
Lead sponsor: POZEN; Industry
Eligibility: 18 Years and older
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Osteo Arthritis Knee
Interventions: Oxycodone, Tramadol, Tylenol, Meloxicam, Gabapentin, Metaxalone, Esomeprazole 20mg; Drug
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Rabeprazole sodium, Esomeprazole; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,061 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Anaheim, California

Conditions: GERD
Interventions: Esomeprazole; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 25
States / cities: Alabaster, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more

Conditions: Healthy
Interventions: LY3410738, Esomeprazole; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Daytona Beach, Florida

Search by objective public record fields.

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec

Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy

A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant

Phase 1 Pharmacokinetics of Intravenous Nexium in Children

Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis

Food Interaction Study To Assess the Effect of Food on the Pharmacokinetics of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)

Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis

Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis

The Effects of Nexium on the Side Effects Associated With a Colonoscopy Prep

Study to Evaluate the Interaction Between Aspirin and Nexium

Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen

The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants